Caribou Biosciences to Evaluate Strategic Alternatives and Halt CAR-T Programs

Key Facts

Caribou Biosciences announced it will evaluate strategic alternatives to maximize stockholder value, according to a statement on GlobeNewswire. The company plans to discontinue its vispa-cel and CB-011 allogeneic CAR-T cell therapy programs as part of this shift. This strategic review often precedes a potential sale, merger, or significant restructuring of the business.

CRBU closed at $1.19 on October 5, 2026, prior to the announcement of the pipeline changes and a planned workforce reduction. The company reported having $113.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026, to support its ongoing strategic transition.